What is the current Global Aminoglycosides Market size?

The Global Aminoglycosides Market is projected to register a CAGR of 4.11% during the forecast period (2024-2029) Read More

Who are the key players in Global Aminoglycosides Market?

Pfizer Inc., AbbVie Inc (Allergan Plc), Teva Pharmaceutical Industries Ltd, Zoetis Inc and Cipla Limited are the major companies operating in the Global Aminoglycosides Market. Read More

Which is the fastest growing region in Global Aminoglycosides Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Global Aminoglycosides Market?

In 2024, the North America accounts for the largest market share in Global Aminoglycosides Market. Read More

What years does this Global Aminoglycosides Market cover?

The report covers the Global Aminoglycosides Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Aminoglycosides Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Aminoglycosides Market - Growth, Size & Share

Aminoglycosides Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Aminoglycosides Market Revenue and the market is segmented by Product (Neomycin, Tobramycin, Gentamycin, Streptomycin, Kanamycin, Paromomycin, Amikacin, Verdamicin, Astromicin, and Hygromycin B), Route of Administration (Parenteral, Intra-mammary, Topical, and Oral), Application (Veterinary, Skin Infection, Respiratory Diseases, UTI and Pelvic Diseases, and Other Diseases), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

Aminoglycosides Industry Overview

The aminoglycosides market is moderately fragmented and competitive. The market studied is composed of a large number of players and includes both small and large pharmaceutical manufacturers. Additionally, the increasing antibiotic resistance has prompted many early-stage biotechnology enterprises to enter this market. The expiry of patent exclusivity has led to large-scale generic manufacturing of aminoglycosides, particularly in the developing region of Asia-Pacific. The key market players include Cipla Limited, Pfizer Inc., AbbVie Inc. (Allergan PLC), Teva Pharmaceutical Industries Ltd, and Zoetis Inc., among others.